Samsung Biologics partners with Enzolytics Inc for antibody therapies

pharmafile | October 8, 2021 | News story | Medical Communications  

Leading manufacturing organisation Samsung Biologics, alongside drug development company Enzolytics, have announced the signing of a strategic CDMO partnership agreement.

Under the terms of this agreement, Samsung Biologics will provide CDMO services that range from cell line development, clinical drug substance, and drug product manufacturing. Enzolytics will leverage Samsung Biologics’ development and manufacturing expertise to advance both anti-HIV and anti-SARS-CoV-2 monoclonal antibody therapies to investigative new drug (IND).

Enzolytics offers the opportunity to implement AI innovation and analysis, and it provides a platform for creating monoclonal antibodies for infectious diseases, which target sites on the virus and offer a cure. The company focuses on the development and commercialisation of treatments for diseases such as HIV-1, Hepatitis (A, B, C), rabies, influenza A and B, tetanus, and diptheria.

 “Partnering with Enzolytics reinforces the value of our fully integrated, end-to-end business model, which is designed to meet the unique needs and goals of our biotech clients,” said John Rim, CEO of Samsung Biologics.

“We look forward to providing comprehensive services and professional support for the manufacturing of this important class of Monoclonal Antibody therapeutics for the treatment of HIV and SARS-CoV-2, helping to accelerate the process of drug development to IND filing and bring these life-saving products to patients.”

Dr. Gaurav Chandra, Chief Operating Officer Research and Development at Enzolytics, added: “The collaboration with Samsung Biologics is a significant milestone for Enzolytics’ Artificial Intelligence enabled Monoclonal Antibody Platform.  We chose to partner with Samsung Biologics because of Samsung Biologics’ extensive experience and expertise in developing, producing, and manufacturing Monoclonal Antibodies for Infectious Diseases and Oncology.”

“This partnership marks a pivotal milestone for Enzolytics to significantly advance the clinical development of our universal, durable, broadly neutralising monoclonal antibodies and reduce time to the clinic and offer the much-needed treatment for patients.”

Lina Adams

Related Content

No items found

Latest content